GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
A sub-population of patients affected by non-small cell lung cancer (NSCLC) with activating
mutations of the epidermal growth factor receptor (EGFR) do not gain benefit from treatment
with tyrosine-kinase inhibitors (TKIs). The hypothesis of this study is that the addition of
chemotherapy with oral vinorelbine to first-line TKI might result in improved outcomes in
EGFR-mutated patients.
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy